CSIMarket
 
Janux Therapeutics Inc   (JANX)
Other Ticker:  
 
 

Janux Therapeutics Inc Growth Comparisons

Select each growth Category to receive further Information



JANX Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q3 MRQ) 38.83 % -4.74 % - -0.55 %
Q / Q Revenue Growth (Q3 MRQ) 138.13 % -0.76 % - -1.18 %
Y / Y Revenue Growth (for 12 months ending Q3 TTM) 105.21 % -5.42 % - %
Seq. Revenue Growth (for 12 months ending Q3 TTM) 9.07 % -1.27 % - 0.08 %
Revenue 5 Year Average Growth - 14.14 % 10.74 % 11.13 %


JANX's Growth Comparisons in III. Quarter 2023




Janux Therapeutics Inc showed impressive 38.83% year on year rise in the third quarter 2023 to 3 millions, despite the -4.74% in the Major Pharmaceutical Preparations industry, Healthcare sector remained unchanged %. Despite modest Sales in the Healthcare sector and the Major Pharmaceutical Preparations industry, Janux Therapeutics Inc reported above average market Sales growth.

Company's sequential Revenue growth rate was impressive 138.13% from the second quarter. Average yearly sales growth for Janux Therapeutics Inc is %, while S & P 500's average annual sales growth is 11.13% over the five years, including only Businesses with the third quarter 2023 financial reports.


Growth Rates of JANX's Income in the third quarter 2023


JANX Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q3 MRQ) - -48.29 % -41.68 % 0.59 %
Seq. Operating Income Change (Q3 MRQ) - 40.17 % 37.14 % 7.23 %
Y / Y Operating Income Growth (Q3 TTM) - -26.2 % -26.59 % -9.01 %
Seq. Operating Income Growth (Q3 TTM) - -14.99 % -12.38 % -0.23 %
Operating Income 5 Year Avg. Change - 33.52 % 10.15 % 10.86 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q3 MRQ) - -68.78 % -77.97 % 1.83 %
Seq. Income from Cont. Ops. Change (Q3 MRQ) - 76.58 % 384.2 % 10.6 %
Y / Y Income from Cont. Ops. Change (Q3 TTM) - -60.94 % -56.82 % -8.43 %
Seq. Income from Cont. Ops. Change (Q3 TTM) - -33.81 % -32.2 % 0.4 %
Income from Cont. Ops. 5 Year Avg. Change - 57.24 % 23.15 % 2.84 %

JANX Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q3 MRQ) - 23.68 % 7.04 % 7.49 %
Q / Q Net Income Growth (Q3 MRQ) - 641.99 % 2333.8 % 14.75 %
Y / Y Net Income Change (Q3 TTM) - -33.18 % -32.49 % -6.17 %
Seq. Net Income Change (Q3 TTM) - 11.16 % 3.48 % 1.93 %
Net Income 5 Year Avg. Growth - 57.4 % 23.18 % 3.12 %

JANX's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q3 MRQ) - -60.89 % -77.97 % 1.83 %
Seq. EPS from Cont. Ops. Change (Q3 MRQ) - 71.87 % 384.2 % 10.6 %
Y / Y EPS from Cont. Ops. Change (Q3 TTM) - - - -
Seq. EPS from Cont. Ops. Change (Q3 TTM) - - - 117.26 %
EPS from Cont. Ops. 5 Year Avg. Growth - 32.23 % 23.15 % 2.84 %



JANX EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q3 MRQ) - 54.96 % 7.04 % 2.84 %
Q / Q EPS Net Growth (Q3 MRQ) - 622.17 % 2333.8 % 14.75 %
Y / Y EPS Net Change (for 12 months ending Q3 TTM) - - - 60498.58 %
Seq. EPS Net Change (for 12 months ending Q3 TTM) - - - 115.79 %
EPS Net 5 Year Avg. Change - 57.4 % 23.18 % 3.12 %



Janux Therapeutics Inc reported bottom-line of $ -0.25 in the third quarter, compare to $ -0.40 in the same quarter a year ago. Major Pharmaceutical Preparations industry grew by 54.96%, while Healthcare sector increased by 7.04%, and overall market improved by 7.49%.

The Company's sequential EPS growth rate was very impressive 138.13% from the second quarter. Average yearly income per share growth for Janux Therapeutics Inc is %, while S & P 500's average annual income per share growth is 3.12% over the five years, including only Businesses with the third quarter 2023 earnings results.

JANX Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q3 MRQ) - 11.75 % 4.9 % 25.82 %
Seq. Free Cash Flow Change (Q3 MRQ) - 112.04 % 51.72 % 28.6 %
Y / Y Free Cash Flow Change (Q3 TTM) - -9.5 % -8.46 % -3.04 %
Seq. Free Cash Flow Change (Q3 TTM) - 3.94 % 2.41 % 11.75 %
Free Cash Flow 5 Year Avg. Change - 27.42 % 18.45 % 23.3 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q3 MRQ) - 43.11 % 8.44 % -
Seq. Net Cash Flow Change (Q3 MRQ) - - - -
Y / Y Net Cash Flow Change (Q3 TTM) - - - -
Seq. Net Cash Flow Change (Q3 TTM) - - 17.06 % -
Net Cash Flow 5 Year Avg. Change - - 0.72 % 48.8 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q3 MRQ) - 1.13 % 3.34 % 69 %
Seq. Capital Expenditures Change (Q3 MRQ) -18.97 % 5.79 % 5.51 % 16.39 %
Y / Y Capital Expenditures Change (Q3 TTM) -56.11 % 8.65 % 5.42 % -8.14 %
Seq. Capital Expenditures Change (Q3 TTM) 54.34 % -0.19 % 0.77 % 18.42 %
Capital Expenditures 5 Year Avg. Change - 13.29 % 9.25 % 8.65 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 







Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com